Gauthier S, Rosa-Neto P, Morais JA, Webster C. World Alzheimer Report 2021: Journey through the diagnosis of dementia. In.; 2021.
Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8(6):595–608.
Article CAS PubMed PubMed Central Google Scholar
Jeremic D, Jiménez-Díaz L, Navarro-López JD. Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: a systematic review. Ageing Res Rev. 2021;72:101496.
Article CAS PubMed Google Scholar
Vyas Y, Montgomery JM, Cheyne JE. Hippocampal deficits in Amyloid-β-Related rodent models of Alzheimer’s Disease. Front Neurosci. 2020;14:266.
Article PubMed PubMed Central Google Scholar
Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat Neurosci. 2010;13(7):812–8.
Article CAS PubMed PubMed Central Google Scholar
Lührs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Döbeli H, Schubert D, Riek R. 3D structure of Alzheimer’s amyloid-β(1–42) fibrils. Proc Natl Acad Sci U S A. 2005;102(48):17342–7.
Article PubMed PubMed Central Google Scholar
Sanchez-Varo R, Mejias-Ortega M, Fernandez-Valenzuela JJ, Nuñez-Diaz C, Caceres-Palomo L, Vegas-Gomez L, Sanchez-Mejias E, Trujillo-Estrada L, Garcia-Leon JA, Moreno-Gonzalez I et al. Transgenic Mouse Models of Alzheimer’s Disease: An Integrative Analysis. Int J Mol Sci 2022, 23(10).
Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70(11):960–9.
Article CAS PubMed Google Scholar
Michno W, Wehrli P, Meier SR, Sehlin D, Syvänen S, Zetterberg H, Blennow K, Hanrieder J. Chemical imaging of evolving amyloid plaque pathology and associated Aβ peptide aggregation in a transgenic mouse model of Alzheimer’s disease. J Neurochem. 2020;152(5):602–16.
Article CAS PubMed Google Scholar
Tamagno E, Guglielmotto M, Monteleone D, Manassero G, Vasciaveo V, Tabaton M. The unexpected role of Aβ1–42 monomers in the pathogenesis of Alzheimer’s Disease. J Alzheimers Dis. 2018;62(3):1241–5.
Article CAS PubMed PubMed Central Google Scholar
Mucke L, Selkoe DJ. Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2012;2(7):a006338.
Article PubMed PubMed Central Google Scholar
Kent SA, Spires-Jones TL, Durrant CS. The physiological roles of tau and Aβ: implications for Alzheimer’s disease pathology and therapeutics. Acta Neuropathol. 2020;140(4):417–47.
Article CAS PubMed PubMed Central Google Scholar
Li S, Selkoe DJ. A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Abeta oligomers from Alzheimer’s brain. J Neurochem. 2020;154(6):583–97.
Article CAS PubMed PubMed Central Google Scholar
Sanchez-Rodriguez I, Djebari S, Temprano-Carazo S, Vega-Avelaira D, Jimenez-Herrera R, Iborra-Lazaro G, Yajeya J, Jimenez-Diaz L, Navarro-Lopez JD. Hippocampal long-term synaptic depression and memory deficits induced in early amyloidopathy are prevented by enhancing G-protein-gated inwardly rectifying potassium channel activity. J Neurochem. 2020;153(3):362–76.
Article CAS PubMed PubMed Central Google Scholar
Sanchez-Rodriguez I, Gruart A, Delgado-Garcia JM, Jimenez-Diaz L, Navarro-Lopez JD. Role of GirK channels in long-term potentiation of synaptic inhibition in an in vivo mouse model of early amyloid-beta Pathology. Int J Mol Sci 2019, 20(5).
Sánchez-Rodríguez I, Temprano-Carazo S, Nájera A, Djebari S, Yajeya J, Gruart A, Delgado-García JM, Jiménez-Díaz L, Navarro-López JD. Activation of G-protein-gated inwardly rectifying potassium (Kir3/GirK) channels rescues hippocampal functions in a mouse model of early amyloid-β pathology. Sci Rep. 2017;7(1):14658.
Article PubMed PubMed Central Google Scholar
Morroni F, Sita G, Tarozzi A, Rimondini R, Hrelia P. Early effects of Aβ1–42 oligomers injection in mice: involvement of PI3K/Akt/GSK3 and MAPK/ERK1/2 pathways. Behav Brain Res. 2016;314:106–15.
Article CAS PubMed Google Scholar
Jiménez-Herrera R, Contreras A, Djebari S, Mulero-Franco J, Iborra-Lázaro G, Jeremic D, Navarro-López J, Jiménez-Díaz L. Systematic characterization of a non-transgenic Aβ(1–42) amyloidosis model: synaptic plasticity and memory deficits in female and male mice. Biol Sex Differ. 2023;14(1):59.
Article PubMed PubMed Central Google Scholar
Takousis P, Sadlon A, Schulz J, Wohlers I, Dobricic V, Middleton L, Lill CM, Perneczky R, Bertram L. Differential expression of microRNAs in Alzheimer’s disease brain, blood, and cerebrospinal fluid. Alzheimers Dement. 2019;15(11):1468–77.
Bai B, Vanderwall D, Li Y, Wang X, Poudel S, Wang H, Dey KK, Chen PC, Yang K, Peng J. Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery. Mol Neurodegener. 2021;16(1):55.
Article CAS PubMed PubMed Central Google Scholar
Zakharova NV, Bugrova AE, Indeykina MI, Fedorova YB, Kolykhalov IV, Gavrilova SI, Nikolaev EN, Kononikhin AS. Proteomic markers and early prediction of Alzheimer’s Disease. Biochem (Mosc). 2022;87(8):762–76.
Horgusluoglu E, Neff R, Song WM, Wang M, Wang Q, Arnold M, Krumsiek J, Galindo-Prieto B, Ming C, Nho K, et al. Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer’s disease. Alzheimers Dement. 2022;18(6):1260–78.
Article CAS PubMed Google Scholar
Jiang Y, Zhou X, Ip FC, Chan P, Chen Y, Lai NCH, Cheung K, Lo RMN, Tong EPS, Wong BWY, et al. Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer’s disease screening and staging. Alzheimers Dement. 2022;18(1):88–102.
Article CAS PubMed Google Scholar
Oláh Z, Kálmán J, Tóth ME, Zvara Á, Sántha M, Ivitz E, Janka Z, Pákáski M. Proteomic analysis of cerebrospinal fluid in Alzheimer’s disease: wanted dead or alive. J Alzheimers Dis. 2015;44(4):1303–12.
Manavalan A, Mishra M, Feng L, Sze SK, Akatsu H, Heese K. Brain site-specific proteome changes in aging-related dementia. Exp Mol Med. 2013;45(9):e39.
Article PubMed PubMed Central Google Scholar
Andreev VP, Petyuk VA, Brewer HM, Karpievitch YV, Xie F, Clarke J, Camp D, Smith RD, Lieberman AP, Albin RL, et al. Label-free quantitative LC-MS proteomics of Alzheimer’s disease and normally aged human brains. J Proteome Res. 2012;11(6):3053–67.
Article CAS PubMed PubMed Central Google Scholar
Yang H, Wittnam JL, Zubarev RA, Bayer TA. Shotgun brain proteomics reveals early molecular signature in presymptomatic mouse model of Alzheimer’s disease. J Alzheimers Dis. 2013;37(2):297–308.
Article CAS PubMed Google Scholar
Gurel B, Cansev M, Koc C, Ocalan B, Cakir A, Aydin S, Kahveci N, Ulus IH, Sahin B, Basar MK, et al. Proteomics analysis of CA1 region of the Hippocampus in Pre-, progression and pathological stages in a mouse model of the Alzheimer’s Disease. Curr Alzheimer Res. 2019;16(7):613–21.
Article CAS PubMed Google Scholar
Ismail R, Parbo P, Madsen LS, Hansen AK, Hansen KV, Schaldemose JL, Kjeldsen PL, Stokholm MG, Gottrup H, Eskildsen SF, et al. The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer’s disease: a longitudinal PET study. J Neuroinflammation. 2020;17(1):151.
Article CAS PubMed PubMed Central Google Scholar
Su L, Surendranathan A, Huang Y, Bevan-Jones WR, Passamonti L, Hong YT, Arnold R, Rodríguez PV, Wang Y, Mak E, et al. Relationship between tau, neuroinflammation and atrophy in Alzheimer’s disease: the NIMROD study. Inform Fusion. 2021;67:116–24.
Ikegawa M, Kakuda N, Miyasaka T, Toyama Y, Nirasawa T, Minta K, Hanrieder J. Mass Spectrometry Imaging in Alzheimer’s Disease. Brain Connect. 2023;13(6):319–33.
Kim C-M, Diez I, Bueichekú E, Ahn S, Montal V, Sepulcre J. Spatiotemporal correlation between amyloid and tau accumulations underlies cognitive changes in aging. J Neurosci. 2024;44(7):e0488232023.
Comments (0)